AnorMED

AnorMED is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic drugs for hematology, human immunodeficiency virus (HIV), and oncology. Its leading drug candidates include MOZOBIL, which is undergoing Phase III clinical trials for cancer patients receiving stem cell transplants, and AMD070, which is being used as an HIV entry inhibitor in Phase Ib/IIa trials.